-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58

Benzinga·08/12/2026 14:07:04
Listen to the news
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $59 to $58.